Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 225.00p on 19-11-2026 at 12:25:15
Change 8.00p 3.69%
Buy 227.00p
Sell 222.00p
Last Trade: Sell 2,000.00 at 222.00p
Day's Volume: 36,197
Last Close: 217.00p
Open: 219.00p
ISIN: KYG4672N1198
Day's Range 219.00p - 232.00p
52wk Range: 153.00p - 239.00p
Market Capitalisation: £1.96b
VWAP: 223.3203p
Shares in Issue: 869.07m

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 2,000 222.00p Ordinary
10:20:36 - 19-Nov-26
Sell* 1,500 225.00p Automatic Execution
10:14:15 - 19-Nov-26
Unknown* 0 230.00p SI Trade
10:02:59 - 19-Nov-26
Sell* 177 228.00p Automatic Execution
10:02:59 - 19-Nov-26
Sell* 2,500 228.00p Ordinary
10:02:09 - 19-Nov-26
Sell* 176 229.00p Automatic Execution
10:02:02 - 19-Nov-26
Sell* 598 230.00p Automatic Execution
10:02:02 - 19-Nov-26
Buy* 2,500 233.00p Ordinary
10:00:48 - 19-Nov-26
Buy* 587 232.00p Automatic Execution
10:00:18 - 19-Nov-26
Buy* 1,000 232.00p Automatic Execution
10:00:18 - 19-Nov-26
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
19th Nov 2026 (Thu) 219.00 232.00 219.00 217.00 36,197
18th Nov 2026 (Wed) 218.00 218.00 215.00 217.00 8,602
17th Nov 2026 (Tue) 221.00 224.00 217.00 224.00 7,375
16th Nov 2026 (Mon) 222.00 225.00 222.00 223.00 7,422
13th Nov 2026 (Fri) 224.00 224.00 219.00 222.00 11,355
12th Nov 2026 (Thu) 224.00 229.00 224.00 227.00 2,649
11th Nov 2026 (Wed) 228.00 235.00 223.00 224.00 107,943
10th Nov 2026 (Tue) 228.00 228.00 227.00 227.00 15,375
9th Nov 2026 (Mon) 224.00 228.00 224.00 228.00 12,088
6th Nov 2026 (Fri) 213.00 220.00 213.00 220.00 16,606
5th Nov 2026 (Thu) 201.00 213.00 201.00 206.00 34,453
4th Nov 2026 (Wed) 195.00 206.00 195.00 206.00 46,488
3rd Nov 2026 (Tue) 197.00 204.00 197.00 204.00 5,804
2nd Nov 2026 (Mon) 198.00 201.00 197.00 201.00 12,468
30th Oct 2026 (Fri) 201.00 201.00 197.00 198.00 21,112
29th Oct 2026 (Thu) 203.00 203.00 202.00 202.00 16,796
28th Oct 2026 (Wed) 207.00 207.00 203.00 206.00 6,879
27th Oct 2026 (Tue) 207.00 212.00 206.00 208.00 13,057
26th Oct 2026 (Mon) 214.00 214.00 210.00 210.00 30,409
23rd Oct 2026 (Fri) 216.00 217.00 213.00 216.00 11,103
22nd Oct 2026 (Thu) 213.00 215.00 208.00 215.00 57,625
21st Oct 2026 (Wed) 227.00 227.00 213.00 213.00 58,887
20th Oct 2026 (Tue) 216.00 222.00 212.00 222.00 73,775
19th Oct 2026 (Mon) 206.00 217.00 206.00 217.00 5,459
See more Hutchmed price history

Hutchmed (HCM) Share News

IN BRIEF: Hutchmed Elunate and Orpathys get expanded NRDL coverage

16th Nov 2026 16:15

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its cancer drugs Elunate and Orpathys will receive expanded coverage under China's National Reimbursement Drug List from January 1, following a contract renewal with the National Healthcare Security Administration. Elunate gains coverage for treating advanced kidney cancer. Orpathys gains coverage for treating advanced lung cancer and is renewed for existing lung cancer treatment. Read More

IN BRIEF: Hutchmed China's sovleplenib designated orphan drug by FDA

5th Nov 2026 14:34

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its autoimmune hemolytic anemia medication sovleplenib was granted orphan drug designation by the US Food & Drug Administration. Medications are eligible for orphan drug designation if they treat rare diseases or conditions affecting fewer than 200,000 people in the US and, if approved for commercialisation, can have 7 years of market exclusivity in the US. The FDA already granted sovleplenib this designation in October for primary immune thrombocytopenia. Sovleplenib is an oral drug that inhibits the enzyme called spleen tyrosine kinase. Hutchmed says sovleplenib's new drug application for both uses is pending in China. Read More

Hutchmed China hails Orpathys acceptance for review in Japan and EU

2nd Nov 2026 14:26

(Alliance News) - Hutchmed China Ltd on Monday said regulatory filings for Orpathys, alias savolitinib, in combination with Tagrisso have been accepted for review in Japan and the EU. Read More

EARNINGS AND TRADING: Seplat revenue up; JPM UK Small Cap merger vote

29th Oct 2026 19:26

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

LONDON BRIEFING: Shell profit doubles; Lloyds earnings jump

29th Oct 2026 07:51

(Alliance News) - Lloyds Banking Group reports a sharp rise in third-quarter profit, while Shell more than doubles its earnings and announces a USD5 billion share buyback. Premier Inn owner Whitbread expects to benefit from UK budget measures limiting business rates increases for hospitality businesses. Read More

See more Hutchmed news
FTSE 100 Latest
Value10,509.13
Change-42.04

Login to your account

Forgot Password?

Not Registered